Innovative Molecular Analysis Technologies (IMAT) Program Program Mission : To support the development, maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation in support of clinical, laboratory, or epidemiological research on cancer. Technology Proof of Advanced Testing & Concept Scale Up Dissemination Development Principle Development Validation Pipeline • Feasibility/Proof-of-principle study R21 ≤$400k over 3 years • Highly innovative technology direct cost support • No preliminary data required • Advanced development & validation phase R33 ≤$900k over 3 years • Demonstration of transformative utility direct cost support • Requires proof of feasibility R43 R44 ≤ $225k over 6m total ≤ $1.5M over 2 years • Development & (regulatory) validation cost support total cost support • Manufacturing & marketing plan • Requires proof of feasibility and • Feasibility study commercialization plan • Clear commercial Fast-Track • Demonstration of transformative utility potential
Open Funding Opportunities for Innovative Technology Development R21 – RFA-CA17- 010: Early‐Stage Innovative Molecular Proof-of-Concept - Analysis Technology Development for Cancer Research no preliminary - Budget: $400k/3yrs (direct cost cap) Molecular/ • data required Cellular R33 – RFA-CA17- 011: Advanced Development and Validation Analysis Optimization/ of Emerging Molecular Analysis Technologies for Cancer - Tools scaling Research Validation Budget: $900k/3yrs (direct cost cap) - • RFA-CA17- 012: Innovative Technologies for Cancer‐ R21 – Relevant Biospecimen Science Sample Proof-of-Concept - Budget: $400k/3yrs (direct cost cap) no preliminary • Quality - data required Assessment RFA-CA17- 013: Advanced Development and Validation R33 – of Emerging Technologies for Cancer‐Relevant & Control Optimization/ - Biospecimen Science Tools scaling Budget: $900k/3yrs (direct cost cap) • Validation - Application deadlines: February 28, May 26, and September 26
IMAT Awards for Small Business Molecular/ Cellular Open to small business entities only Analysis Tools Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care [Most recent issuance: PAR-13-327] Sample R43 • Time: 6 months Quality • Budget: $150k (total cost cap) • Assessment R44 & Control • Time: 2 years • Tools Budget: $2M (total cost cap) •
Diversity of IMAT: Active Projects FY2015 Innovative Technologies for Molecular Application & Validation of Emerging Technologies Analysis of Cancer (R21) for Cancer Research (R33) Optimization/scaling or other further development Initial proof‐of‐concept – o Analytical/technical validation in biological context of Quantifiable milestone driven – o use development plan Current IMAT R21 Portfolio Current IMAT R33 Portfolio Epigenomic Screening (61 Active Projects) (34 Active Projects) Epigenomic Screening Novel Biosensor Novel Biosensor 1 Drug Targeting/Delivery Drug Targeting/Delivery 3 6 Drug Screening 3 Drug Screening 4 7 Advanced Microscopy 4 2 8 Advanced Microscopy Imaging Agents 2 1 Imaging Agents 5 Liquid Biopsy Platform 1 Liquid Biopsy Platform 3 2 4 Genomic screening Genomic screening 3 2 Cancer modeling 5 Cancer modeling 5 4 Sample Preservation 5 Sample Preservation 3 Sample Prep 2 Sample Prep 5 5 Proteomic screening Proteomic screening Transcription screening
http://innovation.cancer.gov
http://innovation.cancer.gov
Recommend
More recommend
